Most of the value in this industry is created not by a drug but by a conversation in the chair (the drug's cost in an injectable's price is 30–50%, industry estimates). Yet the marketing rests on a format that ranks fifth of seven for building trust and is banned by the regulator, while the UK's largest chain went bankrupt in a growing market. This study prices trust — in revenue, and in the multiple paid when the business is sold.
Seven findings. Each carries a confidence rating: high rests on several independent sources, medium on one, estimate means an in-house calculation from stated assumptions.
The European market for drugs and devices is $5.13bn; the market for services is $48.76bn. The product accounts for about 10.5% of the service price. The industry is built so that the drug is a consumable and what sells is the physician's time and judgement.
The global botulinum toxin market is $12.03bn, of which 51.5% is aesthetics, and 98.8% goes to a single drug type. A handful of manufacturers control the gateway to a market worth nearly $49bn, taking a minority of the chain for themselves.
A shortage of qualified injectors is documented as an active constraint on growth. Search interest in procedures is up more than 22% on pre-pandemic levels, the training pipeline can't keep pace, and the cost of labour is rising.
In a survey of 174 providers, 63% of weight-loss-drug patients seeking facial procedures had never used aesthetic medicine before. And they actively resist the overfilled look.
Before-and-after photos rank fifth of seven in a measured trust ranking. In the UK they are banned outright for injectable procedures, along with drug names, hashtags and influencers. 47 enforcement notices were issued in 2024.
The 70-location SK:N chain ceased trading in July 2024 with £35m of debt — in a market growing 11% a year. In a category where the unit of production is a person, economies of scale barely work, while debt works fully.
A single clinic sells for 3–6× EBITDA, a platform for 8–12×. A practice where 30–40% of revenue comes from memberships is worth 0.5–1.0× EBITDA more than an equivalent without them. Repeat behaviour — trust made concrete — has a direct price in the value of the business.
Industry reports give two figures for Europe that differ almost tenfold. This isn't an error but different definitions — and the gap is itself a structural fact.
| Definition | What's counted | Europe, 2026 |
|---|---|---|
| Medical aesthetics | Products and devices: injectables, energy-based devices, implants, cosmeceuticals | $5.13bn |
| Aesthetic medicine | Services and procedures across all care settings, including surgery | $48.76bn |
| Facial injectables | Facial injectable drugs only | $2.53bn |
The estimates come from different research firms with different methodologies, so they can't be added or subtracted. But the ratio of magnitudes is stable and informative: the services market is roughly nine and a half times the size of the products market.
The practical consequence: competing on "our drug is better" is pointless — the drugs are identical and account for a minority of the price. The competition is for the right to decide what to do with that drug.
No figure is taken from a single source without a check. Below: a top-down estimate, a bottom-up estimate and one via procedure volume, brought together.
The procedure-volume check. The International Society of Aesthetic Plastic Surgery records 7.8m botulinum toxin procedures and 6.3m hyaluronic acid procedures a year — but only among plastic surgeons. Dermatologists, cosmetic physicians and medspas aren't in that count, so the true volume is higher, and by how much is unknown.
This is an important caveat: any figure for the number of procedures in the industry is understated, because the count is kept by professional associations, not by the market.
The spread of scenarios to 2031 is $2.5bn — about a third of the market. The optimistic and conservative cases are the author's: the first transfers Germany's rate to all of Europe, the second models a slowdown. What has to hold for the optimistic case: continued inflow of new patients from the weight-loss cohort, and no tightening of regulation beyond the UK. For the conservative case: the spread of the UK regulatory model to the continent.
Germany is the largest and the fastest at the same time — a rare combination that usually signals an immature market with high purchasing power.
| Market | Share and rate | What defines it |
|---|---|---|
| Germany | ≈25% of Europe · 13.5% | Largest and fastest-growing at once. The widest window to enter |
| France | 10.8% | In the top three alongside Germany and the UK |
| UK | 9.1% | Slowest growth among the large markets. Hard ban on advertising prescription drugs |
| Spain | 11.3% | Fastest after Germany, driven by medical tourism |
| France, Italy, UK | >40% of revenue | Together with Germany, form the core of the market |
An observation worth checking separately. The UK grows more slowly than any large market — 9.1% versus Germany's 13.5%. This coincides with the fact that the tightest ban on category advertising operates there. The link is plausible, but causation isn't proven on this data: slow growth may be explained by market maturity rather than regulation. Open sources don't allow the two explanations to be separated.
The section that was missing most. It answers the first question any investor asks: who makes money in this industry.
This is a weak point of the research. On review (Run 12): $5.13bn is the whole European medical-aesthetics market (MarketsandMarkets), not "drugs only"; $48.76bn appears to be a global services aggregate, not European. They can't be divided. The defensible figure is at the procedure level: the drug's cost in an injectable's price is 30–50% (industry COGS estimates). So 50–70% is made in the chair, not "89.5%". The direction of the conclusion is unchanged.
Three consequences, each non-obvious.
First. The drug is an entry ticket, not a product. A clinic competing on the brand of a filler is competing on ten percent of the chain, and doing so against the companies that make that brand.
Second. Economising on the drug is pointless. A 15% discount on input material yields one and a half percent of the final price — while the risk to the outcome rises disproportionately.
Third, and the main one. If most of the value is created by the physician and the conversation, then the defensibility of the business lies there too. Equipment is bought, drugs are ordered, but forty minutes of a trusted conversation cannot be reproduced with money. This moves the study's thesis out of the realm of communications and into the realm of industry structure.
The drugs market is concentrated to a degree that is rarely considered at the clinic level.
Notable manufacturers: AbbVie with the Botox brand, Ipsen with Dysport, Merz with Xeomin, Galderma, Evolus, Revance, plus the Korean firms Medytox, Hugel and Daewoong. The list looks long, but 98.8% of the market is one type of toxin — essentially one product with different labels and different prices.
What this means for a clinic. It has no bargaining power: its purchase volumes aren't comparable to the size of the supplier. But the dependence isn't critical either — the drug is a minority of the service price, and Korean manufacturers create price pressure from below.
Where manufacturer competition is heading. It has shifted to protein-free formulations and long-acting drugs — that is, to whatever promises fewer visits to the physician. Here a conflict of interest arises that the industry talks about little: the manufacturer benefits from a drug that lasts longer, while the clinic makes money on repeat visits. A formula that requires two visits a year instead of three cuts the clinic's revenue by a third at the same drug price.
A separate risk is supply disruption. The US regulator tracks about 270 active drug shortages, and some of them affect the consumables dermatology runs on every day: anaesthetics, sterile injectable forms, certain antibiotics.
A shortage of qualified injectors is described as an active constraint on market growth: demand is rising, the training pipeline isn't keeping up. Search interest in procedures is up more than 22% on pre-pandemic levels, and the density of specialists is unevenly distributed — outside the major centres it is noticeably lower, with faster demand growth.
From this follows a direct economic consequence: the cost of an experienced injector's labour is rising faster than the price of a procedure. Margin is being squeezed not from the drug side but from the wages side.
And from this, too, comes the explanation for why scaling by opening locations doesn't work. Each new location needs not a space but a person the market doesn't have. A space can be leased in a month; an injector with a reputation cannot.
Five forces applied to a single clinic, not to the industry as a whole. The assessment is the author's; the grounds are stated.
A concentrated drugs market, but the product is a minority of the service price, and Korean manufacturers push the price down.
Switching is almost free, prices are opaque and vary twofold, and loyalty rests only on the relationship with a specific physician.
A non-injectable clinic costs from ₴300,000. But licensing and the staff shortage create a barrier that money can't clear.
Weight-loss drugs are changing the structure of demand, home devices are taking the lower segment, and the trend toward restraint is cutting volume per patient.
Fragmentation is extreme, offers are indistinguishable, and price competition suppresses margin for anyone who hasn't differentiated.
The conclusion from the layout. The industry is structurally unattractive to anyone entering with capital and a standard offer: there's no barrier to entry, the buyer is free, competition is dense. It's attractive only to whoever owns the scarce resource — a physician with a reputation and the ability to retain a patient. That is exactly the resource that creates most of the value (see section 05).
A ranking of factors from an international study of patient experience. Respondents distributed weights across seven factors influencing trust in a specialist.
Qualifications and training were named the single most important factor by 46% of respondents. Before-and-after photos rank fifth of seven. Social media presence comes last, with a weight almost three times lower than qualifications.
A separate block measured the quality of the consultation itself. 73% said it was very important that the physician listened to their goals, 58% cited enough consultation time, 54% cited being involved during the procedure. All three concern the conversation, not the outcome.
A separate source — an Australian survey from May 2023 of people considering procedures but not yet decided. Exactly the group missing from the previous study.
Not one barrier is about money. These are three fears — of visibility, of escalation and of judgement — plus the absence of a reference point for timing. All four are removed by a conversation, not a discount.
Note the convergence of two independent studies: those who already go rank qualifications and time spent first; those who haven't decided name fear and the absence of a reference point as the barrier. Both groups describe one need — for a person who will explain and take responsibility.
The most significant shift in demand in recent years, which wasn't in the previous version of the study.
Rapid weight loss on GLP-1 drugs causes loss of soft-tissue volume in the face — a phenomenon that has picked up a colloquial name from the drug brand. This creates demand for volume restoration, skin tightening and planning post-weight-loss care.
In a survey of 174 providers conducted by McKinsey in 2025, 63% of patients in this group who sought facial procedures had never used aesthetic medicine before. About a quarter of clinicians expect the demand to last.
And here is the detail that matters more than volume. These patients, practitioners observe, are acutely aware of the overfilled look and resist it. They want to look like themselves, only thinner — with the structure of the face preserved. Their request meets a cultural shift in the same direction: from the obvious filler toward naturalness and skin quality.
Why this changes the study's conclusions. The thesis about betting on invisibility had until now rested on data about the existing audience. It is now confirmed independently: the fastest-growing new cohort arrives with an explicit request for restraint and without the experience that might have accustomed it to anything else.
What this means in practice. To this cohort, a clinic whose marketing is built on dramatic before-and-after photos looks like a warning, not an invitation. A clinic that says "we'll make it so it won't show" lands in their request word for word.
Caveat. The 63% figure is from a sample of providers, not patients — it is practitioners' perception, not a measurement of behaviour. The direction of the shift is confirmed by several sources; the exact magnitude needs checking.
In the UK the law doesn't restrict the category's marketing — it prohibits almost everything the category does.
| Prohibited | Permitted |
|---|---|
| Naming botulinum toxin and drug brand names | Promoting a consultation about wrinkles without mentioning the drug |
| Workarounds like "treatments that relax wrinkles" | A specialist's qualifications and experience |
| Hashtags that point to the drug | Non-prescription products, e.g. fillers |
| Before-and-after photos: a visual claim even without text | Genuine testimonials that don't mention prescription drugs |
| Discounts, promotions and prize draws involving the drug | Information on the site as one treatment option among others, two clicks from the home page |
| Influencers and celebrities acting as endorsers | An account of the clinic, its equipment and its other services |
| Filters and retouching that exaggerate the effect | — |
Enforcement is not decorative: 47 enforcement notices were issued in 2024 to companies in the industry, mostly for posts on Instagram and TikTok. A clinic's own pages count as advertising on a par with paid ads.
Now line the columns up against the ranking in section 09. What's prohibited is exactly what the industry's marketing is built on. What's permitted is exactly the top three trust factors.
This changes the status of the conclusion: positioning on qualifications and consultation is not an elegant idea but the only lawful construction in Europe's largest regulated market.
There is almost no public data on the revenue of private chains. Below is what open sources confirm.
| Player | Scale | Status |
|---|---|---|
| Thérapie Clinic | 90+ clinics, absorbed Skinsmiths | Claims to be the largest in Europe |
| SK:N Group | 70+ locations, the UK's largest chain | Ceased trading 17 July 2024 |
| Harley Medical Group | Part of the same group | Ceased operations at the same time |
| US market | 10,488 medspas, 81% single locations | 40+ M&A deals a year, three years running |
On 17 July 2024, SK:N Group, Harley Medical Group and ABC Medical ceased trading. More than 70 locations closed and over 450 people lost their jobs. The accounts show £35m of debt due before 2026, a loss of £7.2m in 2021 and £4.5m in 2022.
Thousands of customers who had paid for procedures in advance risked losing their money. An event like this damages trust in the whole category, not just one brand.
The cause wasn't demand — demand was growing. The cause was the model: growth through the number of locations creates fixed costs that, in a category with a ceiling on physician hours, aren't covered by scale. Here the unit of production is a person, not a space.
Two sources calculate acquisition cost differently, and the spread between them is itself informative.
We calculate on gross profit, not revenue — calculating on revenue overstates the metric by about one and a half times. Revenue per customer is $4,775; medspa gross margin is 60–70%; at the 65% median, profit is $3,104. Divide by the median acquisition cost of $250 and you get 12 to 1 against a benchmark of 3 to 1.
More important than the figure is its spread: from 17 to 1 in the best case down to 5 to 1 if leads are handled slowly and acquisition reaches $600. The threefold difference is created not by media cost but by the quality of lead handling.
The second consequence: retention is five to seven times cheaper than acquisition, yet 40% of media budgets go to the top of the funnel.
Calculated per physician, not per clinic — because it is the physician, not the space, that is the constraining resource. All assumptions are stated; the figures are the author's.
| Metric | Value | Basis |
|---|---|---|
| Appointments per day per physician | 5 | At forty minutes per consultation — the limit beyond which the conversation becomes a conveyor belt |
| Working days per year | ≈240 | A six-day week allowing for leave and training |
| Appointments per year | ≈1,200 | Calculation |
| Revenue per customer over 18 months | $4,775 | Industry benchmark |
| Gross margin | 65% | Median of the 60–70% range |
| Ceiling on gross profit per physician | ≈$3.7m over 18 months | Theoretical maximum at full utilisation and zero decline |
This ceiling has to be read with care. It assumes that everyone who walks in becomes a customer for eighteen months, which never happens. The real figure is a multiple lower. But the calculation itself shows the main point: the revenue ceiling of one pair of hands is measured in the millions, not the tens of thousands.
From this comes the explanation for why an acquisition cost of $200–300 isn't a problem in this industry, while the physician shortage is. At that per-person ceiling, fighting to lower the cost per click is working the smallest lever, while every hour of an appointment that didn't happen or was wasted costs incomparably more.
The practical management consequence. A clinic's key metric is not lead cost or average ticket but the share of physician hours spent on people who will actually become patients. That share is what good pre-visit qualification improves, and what a stream of irrelevant enquiries from cheap advertising destroys.
The section that closes the study's logic: it turns trust from an argument into a price.
The spread between a single clinic and a dermatology platform is from 3 to 15× EBITDA — fivefold. Part of the difference is explained by scale, but not all of it.
The section's headline figure. A practice where 30–40% of revenue comes from memberships is valued at 0.5–1.0× EBITDA more than a comparable practice without them. Operators with recurring revenue, a diversified procedure mix and a connection to dermatology or plastic surgery reach 10–12× EBITDA.
A membership is the financial form of trust. A person pays in advance for a relationship that hasn't existed yet. So the market has already priced what the study calls the main scarce resource: roughly one turn of EBITDA for the shift from one-off visits to recurring ones.
How deals are structured. The typical structure is 60–80% cash at close and 20–40% as equity in the combined company. That is, the seller stays invested in the outcome, and the buyer pays not only for the flow but for the physician not going anywhere. This is one more confirmation that what's bought is a person, not a space.
Before-and-after photos are the category's core marketing format. In the measured trust ranking they rank fifth of seven, with a weight of 3.93 against 5.85 for qualifications. In the UK they are banned outright for injectable procedures. And they also repel post-weight-loss patients, 63% of whom came to aesthetic medicine for the first time and actively resist the overfilled look.
Three independent sources — a behavioural study, the regulator and a new demographic — point one way. Budgets go the other.
Differentiating on a format that everyone uses and that is banned is impossible. The position is built on the top three trust factors — proven qualifications, a genuine reputation and time for a conversation. All three are permitted by law, all three copy badly, and all three create most of the value (see section 05).
And that position now has a price: roughly one turn of EBITDA for the shift from one-off visits to recurring ones.
The same conclusion means different things for a clinic owner, an investor and a manufacturer. Below are three different lists of actions.
The section without which the study can't be called honest. Also here: what to find out next.
The value-chain split was wrong (Run 12). $5.13bn is the whole European medical-aesthetics market, not "drugs"; $48.76bn is a non-comparable global services figure. Replaced with the procedure-level COGS: drug is 30–50% of an injectable's price, so 50–70% is made in the chair.
There are no manufacturer market shares. The list of players and the total volume are known; the split between them isn't found in open sources.
Procedure volume is understated. The count is kept by professional associations of plastic surgeons; dermatologists, cosmetic physicians and medspas don't make it into the statistics. By how much exactly is unknown.
Seasonality isn't measured. It certainly exists in the category; no numerical data could be found.
The trust data is geographically skewed — 59% of the sample is Australian, and it dates to 2020–2021.
The 63% figure for the new cohort is practitioners' perception, not a measurement of patient behaviour. The direction of the shift is confirmed; the magnitude needs checking.
The multiples are taken from the US market. European deal data could not be found in the open; this is a transfer by analogy.
The link between hard regulation and slow growth in the UK is not proven, only noticed. The regulation effect and the market-maturity effect can't be separated on this data.
Every figure in the study in one table, with a note on where it came from and how far it can be trusted.
| Metric | Value | Source and status |
|---|---|---|
| Market size | ||
| Europe, drugs and devices, 2026 | $5.13bn | Report, fact |
| Europe, same, 2031 | $8.64bn | Report, forecast |
| CAGR | 11.0% | Report, forecast |
| Europe, services, 2026 | $48.76bn | Different report, different definition |
| Europe, facial injectables, 2026 | $2.53bn | Report, fact |
| Global botulinum toxin market, 2026 | $12.03bn | Report, fact |
| Aesthetics' share of it | 51.5% | Report, 2025 |
| Type A share | 98.8% | Report, 2025 |
| North America's share | 58.7% | Report, 2025 |
| Global fillers market, 2023 | $5.08bn | Report, fact |
| Volumes and structure | ||
| Botulinum toxin procedures worldwide per year | 7.8m | ISAPS, plastic surgeons only |
| Filler procedures | 6.3m (+5.2%) | ISAPS, same |
| Clinics' share of end users | 55.2% | Report, 2024 |
| Facial aesthetics' share of revenue | 55.0% | Report, 2025 |
| Medspas in the US | 10,488 | Report, 2023 |
| Of which single locations | 81% | Report, fact |
| In chains and fund platforms | 8% | Report, fact |
| Geography | ||
| Germany, share of Europe | ≈25% | Report, fact |
| Germany, growth | 13.5% | Report, forecast |
| Spain, growth | 11.3% | Report, forecast |
| France, growth | 10.8% | Report, forecast |
| UK, growth | 9.1% | Report, forecast |
| Acquisition economics | ||
| Acquisition cost, typical | $200–300 | Primary source read |
| Same with slow handling | up to $600 | Same |
| Injectables, Google Ads | $90–160 | Industry review |
| Body contouring | $160–280 | Same |
| Consultation in major cities, 2024 | $180–320 | Primary source, up from $120–210 in 2022 |
| Revenue per customer over 18 months | $4,775 | Primary source, explicitly revenue |
| Medspa gross margin | 60–70% | Industry review |
| Gross profit per customer | $3,104 | Author's calculation |
| Profit-to-acquisition ratio | 12 to 1 | Author's calculation |
| Cost to retain | $35–85 | Industry review |
| Return on ad spend, average | 3.62× | Primary source |
| Return for top performers over 18 months | 7–7.6× | Same |
| Share of revenue to marketing | 7–12% | Industry review |
| Audience behaviour | ||
| Qualifications as a trust factor | weight 5.85 | CIPEES, 46% named it most important |
| Reputation | 4.82 | Same |
| Time spent | 4.52 | Same |
| Before-and-after photos | 3.93 | Same, fifth place |
| Social media presence | 1.69 | Same, last |
| A natural result matters | 85% | Australian survey, May 2023 |
| Fear of the "slippery slope" | 27% | Same |
| Fear of judgement | 22% | Same |
| New GLP-1 patients with no prior experience | 63% | Survey of 174 providers, practitioners' perception |
| Regulation and capital markets | ||
| UK regulator enforcement notices, 2024 | 47 | Industry source |
| Single clinic, multiple | 3–6× EBITDA | Investment-bank review, US |
| Standalone medspa | 4–7× | Same |
| Regional chain | 5–8× | Same |
| Platform, 15+ locations | 8–10×+ | Same |
| Dermatology with aesthetics | 12–15× | Same |
| Uplift for memberships at 30–40% of revenue | +0.5–1.0× | Same, the key figure in section 16 |
| Deal structure | 60–80% cash | Same |
| The SK:N bankruptcy | ||
| Date trading ceased | 17.07.2024 | Official notice |
| Locations closed | 70+ | Press |
| Jobs lost | 450+ | Press |
| Debt due | £35m | Accounts |
| Loss 2021 / 2022 | £7.2m / £4.5m | Accounts |